Gossamer Bio, Inc (NASDAQ:GOSS) is one of the 10 Best High-Risk Penny Stocks to Buy Right Now. Gossamer Bio, Inc (NASDAQ:GOSS) reported its fourth-quarter results on March 17, delivering a mixed performance as earnings missed expectations while revenue came in stronger than expected. The company posted a GAAP loss of $0.21 per share, falling short of estimates by $0.02 per share. On the revenue side, sales reached $13.8 million, representing a 47.8% year-over-year increase. The figure beat consensus estima ...

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Gossamer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On February ...

Core Viewpoint - Gossamer Bio, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws, particularly related to its lead pipeline candidate, Seralutinib, and the PROSERA study results [1][4]. Group 1: Company Overview - Gossamer Bio's lead pipeline candidate is Seralutinib, which was evaluated in the PROSERA study, a pivotal Phase 3 trial for pulmonary arterial hypertension [2]. - The PROSERA patient population was characterized by the company as well-suited to demonstrate a treatment effect [2]. Group 2: Trial Results - During the Q1 2025 earnings call, CEO Faheem Hasnain expressed optimism about the trial results, stating that the baseline characteristics were "precisely what we have targeted" and that the company had "over 90% power given the sample size" [3]. - Despite reaching the planned enrollment target, the primary efficacy endpoint of the trial did not achieve the prespecified level of statistical significance [3].

Core Insights - Gossamer Bio, Inc. (NASDAQ:GOSS) is currently highlighted as one of the most active penny stocks to consider for investment [1] - As of March 16, 2026, 44% of analysts maintain a "Buy" rating for Gossamer Bio, with a consensus price target of $1.00, indicating an upside potential of 117.39% [2] - Recent revisions in forecasts for Gossamer Bio's primary therapy, seralutinib, are attributed to an uncertain regulatory environment [2] Analyst Ratings and Price Targets - H.C. Wainwright & Co. has maintained a "Buy" rating but reduced its price target from $10 to $5, citing a lowered probability of success for seralutinib in pulmonary arterial hypertension (PAH) from 70% to 50% [3] - Oppenheimer & Co. reiterated its "Outperform" rating while lowering its price target from $12 to $3, noting that upcoming FDA interactions and data could mitigate risks associated with seralutinib's approval pathway [4] Company Overview - Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for immunology, inflammation, and oncology, with notable projects including GB001 for eosinophilic asthma [5]

GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails Accessibility StatementSkip NavigationGossamer Bio CEO Expressed Optimism About PROSERA Trial Outcome; the Study Missed Its Primary Endpoint Months LaterNEW YORK, March 18, 2026 /PRNewswire/ -- Gossamer Bio, Inc. (NASDAQ: GOSS) shareholders suffered significant losses when the Company disclosed that its Phase 3 PROSERA study of seralutinib missed its primary 6-minute walk distance endpoint in pulmonary ...

分组1 - Gossamer Bio reported a quarterly loss of $0.21 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.20, representing an earnings surprise of -7.14% [1] - The company posted revenues of $13.8 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 81.52%, compared to $9.38 million in the same quarter last year [2] - Gossamer Bio shares have declined approximately 85.3% since the beginning of the year, contrasting with the S&P 500's decline of 2.1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $6.03 million, and for the current fiscal year, it is -$0.55 on revenues of $19.79 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stocks in this sector [8]

Financial Performance - Total revenue for the fourth quarter of 2025 was $13.8 million, compared to $9.4 million for the same period in 2024, representing a 47.5% increase[16] - Net loss for Q4 2025 was $47.2 million, or $0.21 per share, compared to a net loss of $33.0 million, or $0.15 per share, for Q4 2024[12] - Total operating expenses for the full year 2025 were $219.2 million, compared to $174.6 million for 2024, reflecting a 25.5% increase[16] - The accumulated deficit as of December 31, 2025, was $1.44 billion, compared to $1.27 billion at the end of 2024[17] Research and Development - Research and Development (R&D) expenses for Q4 2025 were $48.9 million, up from $36.1 million in Q4 2024, marking a 35.5% increase[11] - In the PROSERA study, seralutinib showed a placebo-adjusted improvement in six-minute walk distance of approximately +13.3 meters at Week 24, although it did not meet the prespecified statistical threshold[6] Regulatory and Clinical Updates - The company plans to request a Type C meeting with the FDA in June 2026 to discuss the PROSERA dataset and potential regulatory paths forward[10] - Enrollment in the Phase 3 SERANATA Study in PH-ILD has been paused while the company evaluates the implications of PROSERA results[5] Operational Changes - The company implemented a reduction in force to align resources with near-term priorities[8] - Cash, cash equivalents, and marketable securities totaled $136.9 million as of December 31, 2025, down from $294.5 million at the end of 2024[17]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________________________________________________________________________ FORM 10-K __________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38796 _____ ...

Group 1 - Gossamer Bio, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws [1] - The company's lead pipeline candidate, Seralutinib, was evaluated in the PROSERA study, a pivotal Phase 3 trial for pulmonary arterial hypertension [2] - During the Q1 2025 earnings call, the CEO expressed optimism about the trial's results, stating that the baseline characteristics were targeted and that there was "over 90% power given the sample size," although the primary efficacy endpoint did not achieve statistical significance [3] Group 2 - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [5]

Core Viewpoint - The pre-earnings options volume for Gossamer Bio (GOSS) is normal, with a notable preference for puts over calls at a ratio of 19:3, indicating bearish sentiment ahead of earnings release [1] Options Activity - The implied volatility suggests that the market is anticipating a significant price movement of approximately 46.1% following the earnings results [1] - The median price movement for Gossamer Bio over the past eight quarters has been 3.5%, indicating a historical context for expected volatility [1]